The Journal of Pediatrics
Volume 152, Issue 5 , Pages 685-689 , May 2008

Double-blind Placebo-Controlled Trial of Amitriptyline for the Treatment of Irritable Bowel Syndrome in Adolescents

  • Ron J. Bahar, MD

      Affiliations

    • Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, UCLA Geffen School of Medicine, Los Angeles, CA
    • Corresponding Author InformationReprint requests: Ron Bahar, MD, UCLA Geffen School of Medicine, 5363 Balboa Blvd, Suite 540, Encino, CA 91316.
    • ,
  • Brynie S. Collins, MD

      Affiliations

    • Children's Hospital Los Angeles, Keck-USC School of Medicine, Los Angeles, CA.
    • ,
  • Barry Steinmetz, MD

      Affiliations

    • Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, UCLA Geffen School of Medicine, Los Angeles, CA
    • ,
  • Marvin E. Ament, MD

      Affiliations

    • Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, UCLA Geffen School of Medicine, Los Angeles, CA

Received 1 June 2007 ,Revised 27 September 2007 ,Accepted 15 October 2007.

  • Image Result

    Percent of IBS patients in AMI and Placebo groups with at least 15% improvement from baseline in overall QOL score.

    Percent of IBS patients in AMI and Placebo groups with at least 15% improvement from baseline in overall QOL score.

  • Image Result

    Change in overall QOL scores from week 0 in AMI vs. Placebo treated IBS Patients (mean ± SEM).

    Change in overall QOL scores from week 0 in AMI vs. Placebo treated IBS Patients (mean ± SEM).

 Supported by James L. Brooks and the Diane Brooks Medical Research Foundation of the California Community Foundation (Los Angeles, CA), as well as by AstraZeneca, LP (Wayne, PA).

PII: S0022-3476(07)00976-6

doi: 10.1016/j.jpeds.2007.10.012

The Journal of Pediatrics
Volume 152, Issue 5 , Pages 685-689 , May 2008

Article Tools

* Image Usage & Resolution